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Abstract 
Background Concern of transfusion-transmitted bacterial infections has been the major hurdle to 
extend shelf life of platelet concentrates. We aimed to investigate the association between storage time 
and risk of positive blood cultures at different times after transfusion.  
Methods We performed a nationwide cohort study among platelet transfusion recipients in Denmark 
between 2010 and 2012, as recorded in the Scandinavian Donations and Transfusions (SCANDAT2) 
database. Linking with a nationwide database on blood cultures (MiBa), we compared the incidence of a 
positive blood culture among recipients of platelets stored six to seven days (old) to those receiving 
fresh platelets (one to five days), using Poisson regression models. We considered cumulative exposures 
in windows of one, three, five, and seven days.  
Results A total of 9,776 patients received 66,101 platelet transfusions. The incidence rate ratio of a 
positive blood culture the day after transfusion of at least one old platelet concentrate was 0.77 (CI 
0.54-1.09) compared to transfusion of fresh platelet concentrates. The incidence rate of a positive blood 
culture was lower the day after receiving one old compared to one fresh platelet concentrate (IRR 0.57; 
CI: 0.37-0.87). Three, five or seven days after transfusion, storage time was not associated with the risk 
of a positive blood culture.  
Conclusion Storage of buffy coat derived platelet concentrates in PAS-C up to seven days seems safe 
regarding the risk of a positive blood culture. If anything, transfusion of a single old platelet concentrate 
may decrease this risk the following day.  
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Introduction 
Platelet concentrates are transfused to prevent or treat bleeding complications in patients with low 
platelet count or severe platelet dysfunction. In contrast to other blood components, platelet 
concentrates are stored at room temperature which may facilitate bacterial growth.(1) Bacterial sepsis 
caused by transfusion of contaminated blood products currently constitutes the largest transfusion-
associated infectious risk.(2) In many blood centers, platelet concentrates are screened for bacterial 
contamination in an attempt to reduce this risk.(3, 4) However, such screening is costly and is limited by 
false negative test results.(2, 5) 
Because most reported septic transfusion reactions were associated with platelet concentrates stored 
for 4 days or more, older platelet concentrates are believed to increase the risk of transfusion-
associated bacterial infections.(6-9) A reduction of the maximum permitted storage time of platelet 
concentrates could conceivably reduce this risk. Therefore, storage time has been limited to 3.5 days in 
Japan and 4 days in Germany.(4, 10) Such a strategy might increase rates of product outdating and limit 
the number of components in stock to cope with emergency situations.(11) In several countries, 
including the Netherlands and Denmark, platelet concentrates can be stored for up to seven days in 
combination with bacterial screening.(4) 
Besides a direct risk of transfusion-transmitted bacterial infections, platelets could also modulate the 
immune response and thereby influence the risk of infections. During storage several cytokines and 
chemokines, which could have immunomodulatory effects, are released.(12)  
We have previously shown that the overall risk of bacteremia of any cause was decreased in 
hematological patients one day after transfusion of platelet concentrates stored five to seven days as 
compared to patients who received units stored one or two days. The association was limited to 
transfusion of platelet concentrates stored in plasma, whereas storage time was not associated with the 
risk of all-cause bacteremia when the platelets were stored in platelet additive solution (PAS). However, 
the power of the latter analysis was limited by the sample size for platelets stored in PAS-C and the 
maximal storage time of five days for platelets in PAS-B.(13)  
In Denmark, all platelet concentrates are stored in PAS-C with a maximal storage time of seven days. The 
current study aimed at investigating the effect of storage for six or seven days on risk of a positive blood 
culture at different times after transfusion in all recipients of a platelet transfusion by using 
administrative health care data. 
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Methods 
Setting 
We performed a nationwide cohort study among all patients receiving platelet transfusions in Denmark 
between 2010 and 2012. For the purpose of the present study, we restricted the study population to 
patients who were 18 years or older at transfusion. To ensure a homogeneous patient population, 
hospitals administering less than 1000 platelet transfusions during the study period were excluded. The 
study was approved by the Danish Data Protection Agency (2015-57-0012). 
Data sources 
We obtained information on transfusion recipients and blood components from the Scandinavian 
Donations and Transfusions database (SCANDAT2), which has been described in detail elsewhere.(14) In 
brief, data on donations and transfusions were collected from blood banks covering all of Sweden and 
Denmark. Data were linked to national registers of migration, death, and hospital care, using the unique 
personal identification number assigned to all residents of Sweden and Denmark.  
Recipient data included information on sex, blood group, dates of birth, death and migration, discharge 
diagnoses, and procedure codes. Data on blood components included date of donation and transfusion, 
type of blood component, and blood group of donor(s). For the current study we selected the 
transfusions to Danish residents.  
Information on blood culture results was obtained from MiBa, the Danish microbiology database.(15) 
MiBa contains copies of reports from all Danish departments of microbiology with a sampling date 
between 1 January 2010 and 31 December 2012. Blood cultures were taken on clinical indication or 
routinely as part of certain treatment protocols, not necessarily directly related to the transfusion. This 
information was linked to the transfusion data via the personal identification number. 
Exposure 
Platelet concentrates were produced from buffy coats of four ABO and Rhesus D matched donors and 
re-suspended in platelet additive solution (PAS-C, Intersol, Fenwal TM ). Buffy coats are pooled 3 to 30 
hours after donation, but preferably after overnight hold of whole blood. All platelet concentrates were 
screened for bacterial contamination using the BacT/Alert system, consisting of an aerobic bottle, which 
is inoculated with 5-10 ml. Sampling is performed right after pooling of the buffy coats. (4) Products are 
released according to a ‘negative-to-date’ procedure. Maximum storage time of platelet concentrates 
was seven days. Storage time was counted in days from the day of donation (day 0) up to and including 
the day of transfusion. Platelet concentrates stored for six or seven days were considered ‘old’ and 
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platelet concentrates stored for one to five days were considered ‘fresh’. Approximately 3% of all 
platelet concentrates were collected via apheresis. These products were taken into account when 
adjusting for total number of transfusions, but we did not study storage time of apheresis products, as 
most of these were given for specific indications.  
Outcome 
The primary outcome of interest was a positive blood culture, regardless of the cause. Patients could 
develop a positive blood culture multiple times during the study period. Two consecutive positive 
cultures were considered to be unrelated if separated by at least 14 days.  
Statistical analysis 
The main analysis tested whether the occurrence of a positive culture on a given day was associated 
with transfusion of at least one old platelet unit during the preceding one to seven days. We employed a 
sliding window approach, with an exposure ascertainment period of one, three, five, or seven days with 
a subsequent 1-day follow-up period during which we ascertained the occurrence of a positive blood 
culture(Figure 1). Patients were considered at risk if they received at least one platelet concentrate 
during the window period and did not have a positive blood culture within the previous 14 days. For 
each day of follow-up we then advanced both the exposure and outcome ascertainment periods one 
day at a time. Because both transfusions and blood cultures were only recorded per calendar day, it was 
not possible to know whether blood cultures were drawn before or after a transfusion. We therefore 
excluded follow-up on days on which a transfusion was given.  
The incidence rate of a positive blood culture after transfusion of at least one old platelet concentrate 
was compared with the incidence rate after transfusion of only fresh platelet concentrates, using 
Poisson regression. The analyses were adjusted for day of the week, rhesus D antigen positivity of the 
product, and hospital, using stratification of person time. Day of the week and rhesus D antigen 
positivity were treated as time-dependent variables, based on the last transfusion given during that 
window period. We did not adjust for any patient characteristic, as storage time is not known by the 
treating physician and therefore confounding by indication is unlikely to arise. Robust variance estimates 
were used, as patients could contribute more than one window period, of which each may be 
terminated by a positive blood culture.(16) 
The number of platelet transfusions a patient received during a window period could confound the 
association between storage time and risk of a positive blood culture, as number of transfusions is a 
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strong indicator of sickness of the patient and risk of receiving at least one old platelet concentrate. 
Therefore, we stratified on number of platelet transfusions: one, two, three, and four or more 
transfusions during the window period. For the one-day window period analyses were stratified on one, 
two, and three or more transfusions. 
Additional analyses 
We performed three additional analyses. First, we assessed the effect of receiving at least one old 
platelet concentrate in a subgroup of patients with a hematological malignancy or aplastic anemia. This 
subgroup was established using the sequential algorithm used in previous studies, based on diagnosis 
and procedure codes.(17-19) Here we did not differentiate between main and co-diagnoses in the 
hospital register data. The covariates and stratification were the same as in the main analysis.  
Second, to test for a dose-response relationship, we modeled the number of old products as main 
exposure, stratified on number of platelet transfusions and adjusted for the same confounders as in the 
main analysis. 
Third, we included also transfusions given during the follow-up days in the analysis to investigate 
whether we introduced selection bias by excluding these days. Specifically, it has been suggested that 
the time to the next transfusion is shorter after transfusion of an old platelet concentrate than after 
transfusion of a fresh concentrate.(20-22) Therefore, we could have excluded more follow-up time, and 
thereby probably more events, after transfusion of old platelet concentrates, which could have 
introduced selection bias.  
All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, North Carolina), 
using the GENMOD procedure. For stratification and aggregation of follow-up time the stratify macro 
was used.(23) 
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Results  
Patient characteristics 
Between 2010 and 2012, a total of 12,529 patients received at least one platelet transfusion in 
Denmark. Of these, 826 patients were excluded based on age at time of transfusion and 1,927 patients 
were excluded as they only received a transfusion in a hospital that accounted for fewer than 1000 
platelet transfusions in the study period. The final cohort consisted of 9,776 patients, more men than 
women (62.3% versus 37.7%), with an average age of 64.1 years (Table 1). During the study period, 
these patients received 66,101 platelet concentrate transfusions, of which 22,240 units (33.6%) were 
stored for six or seven days. This relatively large proportion of old platelet concentrates is a 
consequence of the first-in-first-out policy. Forty-nine percent of all platelet concentrates were 
transfused to patients with a hematological malignancy, 15.6% to patients with trauma or burns, and 
8.6% to patients who underwent cardiothoracic surgery. The distribution of diagnoses was similar 
among the storage time categories. Information about blood group of the product was missing for 
11,156 products, but this was equally distributed among the storage time categories. The proportion of 
rhesus D negative products increased with increasing storage time (Table 2). 
Incidence of positive blood cultures 
The day after transfusion 211 cases of positive blood cultures occurred, which corresponds to an 
incidence rate of 8.0 per 1000 observation days (95% confidence interval (CI) 7.0 to 9.2). Among patients 
receiving a transfusion within the last three days, the incidence rate was 6.5 per 1000 days (95% CI 5.9 
to 7.2). Considering a five day window period the incidence rate was 5.7 per 1000 days (95% CI 5.2 to 
6.2) and for the seven day window period this was 5.2 per 1000 days (95% CI 4.8 to 5.7). The incidence 
rate increased with an increasing number of platelet transfusions in all window periods (Figure 2). 
Old versus fresh platelet concentrates 
Figure 3 presents the incidence rate ratios (IRR) of a positive blood culture after transfusion of at least 
one old platelet concentrate, compared to only fresh platelet concentrates, for all window periods, 
stratified on total number of platelet transfusions. The incidence rate ratio of a positive blood culture 
the day after transfusion of at least one old platelet concentrate compared to only fresh platelet 
concentrates was 0.77 (95% CI 0.54 to 1.09). Considering a window period of three days, the incidence 
rate ratio of a positive blood culture was 0.96 (95% CI 0.76 to 1.23). This was 0.98 (95% CI 0.79 to 1.21) 
for a five day window period and 1.05 (95% CI 0.87 to 1.28) for a seven day window period 
(supplemental data). 
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For patients receiving a single platelet concentrate, the incidence rate of a positive blood culture the day 
after transfusion was lower if this was an old platelet concentrate (IRR 0.57; 95% CI 0.37-0.87). This 
association was not statistically significant if the old platelet concentrate was transfused in the 
preceding three, five or seven days (Figure 3). 
Additional analyses 
For patients with a hematological malignancy or aplastic anemia, the incidence rate ratio of bacteremia 
the day after transfusion of at least one old platelet concentrate was 0.54 (CI 0.31 to 0.87) compared to 
transfusion of only fresh platelet concentrates. After receiving a single old, compared to a single fresh, 
platelet concentrate the incidence rate ratio was 0.44 (95% CI 0.26 to 0.76). If a patient received one old 
platelet concentrate in the preceding three, five, or seven days, the estimates were similar, although not 
statistically significant (Figure 3, panel B and supplemental data).  
There was no evidence of a dose-response relationship (Table 3). For patients who received two 
transfusions, the incidence rate ratio for a positive blood culture the day after receiving exclusively old 
platelet concentrates compared to exclusively fresh platelet concentrates was 1.11 (95% CI 0.53 to 
2.31). Similar estimates were observed for patients receiving three, or four or more platelet 
concentrates and if these transfusions were given during a longer window period (Table 3). 
Including the follow-up days on which a patient had received a platelet transfusion did not change the 
results (supplemental data). 
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Discussion 
In this nationwide cohort study, transfusion with platelet concentrates stored for six or seven days was 
not associated with an increased risk of a positive blood culture compared to transfusion with platelet 
concentrates stored for five days or less. If anything, risk of a positive blood culture was lower the day 
after transfusion of one old platelet concentrate compared to one fresh platelet concentrate.  
Storage time was only associated with a lower incidence of a positive blood culture after transfusion of a 
single platelet concentrate. The lack of an association when patients had received multiple transfusions 
might conceivably be attributable to effect modification by indication or underlying morbidity. 
Specifically, diagnoses and indications might differ between patients who need only one transfusion and 
those who need more transfusions. As corollary, the patients who needed the most transfusions might 
also have a higher baseline risk of infection. The increased incidence of a positive blood culture with an 
increasing number of transfusions, as observed in the present study, would be compatible with this 
notion. Hence, under such circumstances any variation in infection risk by storage time of a transfused 
product might be clinically irrelevant and immeasurable. In addition, the groups receiving multiple 
transfusions were smaller which limits the power to detect such small effects.  
The protective effect of an old platelet concentrate was only seen after the shortest window period. 
Most hematological patients receive prophylactic antibiotics, which could result in negative blood 
cultures after three or more days, but maybe not immediately the day after transfusion. The higher risk 
of a positive blood culture soon after transfusion of fresh platelets could be due to contamination which 
was not yet detected by the bacterial screening system. Not all bacteria are able to proliferate within a 
platelet concentrate, so during storage a blood component could auto-sterilize.(2, 24, 25) However, 
studies have shown that platelet concentrates transfused before the screening turned out positive only 
marginally increase the risk of clinically significant infections.(26, 27) Another postulated theory is that 
platelets play a role in the immune system and transfusions could modulate this response. (12, 28, 29) 
During storage, efficacy of platelets reduces: referred to as ‘the storage lesion’.(30, 31) This may imply 
that older platelets are not consumed immediately in hemostatic activities and still exert a relatively 
higher activity of non-hemostatic functions that may protect the patient better against infections.  
The reduction in efficacy during storage could also have introduced selection bias, as we excluded 
follow-up time in which a patient received a transfusion and the interval between transfusions may be 
shortened after transfusion of old platelet concentrates.(32) However, the sensitivity analysis including 
follow-up time in which a patient received a transfusion yielded similar results. 
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A major strength of our study is that we were able to study storage of platelet concentrates for up to 
seven days. In many countries storage is limited to five days, but blood banks worldwide are seeking to 
extend their maximum storage time.(33) The draft guidance of the FDA stated that transfusion of 
platelet concentrates stored for six or seven days is allowed, provided that these concentrates are 
cultured again on day four or five of storage, or rapid testing is performed within 24 hours prior to 
transfusion. However, no culture system has been certified up to now.(34) 
Studies regarding transfusion-associated sepsis are often based on data gathered by passive 
surveillance. It has been suggested that such a strategy underestimates the true incidence as much as 
40-fold.(35, 36) We included all positive blood cultures as a surrogate outcome to overcome this 
underestimation. Such a strategy implicates that we also included blood cultures that were positive due 
to contamination of the culture and not the result of a bacteremia accompanied by clinically relevant 
symptoms. Bacteria identified in contaminated blood cultures are often skin derived and the same as 
those identified in contaminated blood products and transfusion-transmitted infections.(27) It is 
therefore impossible to distinguish between these. As a consequence, the incidence in our study 
overestimates the true incidences of all-cause bacteremia and transfusion transmitted bacterial 
infections. As contamination of blood cultures is unrelated to storage time of platelet concentrates, this 
misclassification may have biased the results towards the null, meaning no association. Moreover, since 
we used positive blood cultures as a surrogate outcome for bacteremia, we are unable to completely 
rule out the potentially fatal residual risk of septic transfusion reactions after screening. This especially 
accounts for older products. Sampling for the BacT/Alert is performed 24 hours after donation, so initial 
low inocula could be missed, resulting in false negative screening. Proliferation during storage may 
result in a high bacterial load at time of transfusion and an increased risk of severe septic transfusion 
reactions.(37, 38) The same kind of bias applies to transfusion of other blood products. It has been 
suggested that red cell transfusions also have immunomodulatory effects. However, transfusion of other 
blood products is not associated with storage time of platelet concentrates. (32, 39)  Therefore, these 
additional transfusions could not confound our results.  
These biases could potentially explain the lack of an association in patients who received multiple 
platelet concentrates. However, they are unlikely explanations of our observation of a protective effect 
of transfusion of a single old platelet concentrate on the incidence of positive blood cultures. 
The present findings are consistent with the results of our previous study. In a population of Dutch 
hematological patients, the risk of bacteremia was lower the day after transfusion of platelet 
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concentrates stored in plasma for five to seven days compared to those stored one or two days.(13) In 
the Dutch study, we only included days on which a patient received platelet concentrates exclusively of 
a single storage time category. On most analyzed days, patients received only one transfusion. 
Therefore, these results are comparable with the conclusion of the current study regarding transfusion 
of a single old platelet concentrate. Since we now have found a similar effect in two independent 
cohorts, using different methods, it is unlikely that this association has arisen from chance alone. 
To conclude, regarding the risk of a positive blood culture, it seems to be safe to store platelet 
concentrates up to seven days in combination with 100% screening. Transfusion of a single old platelet 
concentrate may decrease the risk of a positive blood culture the day after transfusion, especially in 
patients with a hematological malignancy. 
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Table 1. Characteristics of study population 
 Number of patients (%) 
Patients, n 9,776 
Male, n (%) 6,088 (62.3) 
Age, n (%)  
18-49 years 1,533 (15.7) 
50-74 years 6,011 (61.5) 
≥75 year 2,232 (22.8) 
Mean (SD) age in years 64.1 (14.6)      
Median (IQR) number of transfused platelet concentrates 2 (1-6)         
Median (IQR) number of transfused red blood cell concentrates 12 (5-24)  
Median (IQR) number of transfused plasma products 2 (0-8)  
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Table 2. Characteristics of transfused platelet concentrates 
 Storage time 1-5 days Storage time 6 -7 days Total 
Number of platelet 
concentrates (%)* 
34,722 (52.5) 22,240 (33.6) 66,101 (100) 
Male, n(%)† 21,628 (62.3) 14,151 (63.6) 41692 (63.1) 
Mean (SD) age in years† 60.3 (14.9) 60.0 (15.1) 60.2 (14.9) 
Median (IQR) number of prior 
transfusions all products 
32 (9-79) 33 (9-83) 34 (10-84) 
Main indication    
Hematology 17,029 (49.0) 10,681 (48.0) 32,547 (49.2) 
Cardiothoracic surgery 3,017 (8.7) 1,914 (8.6) 5,657 (8.6) 
Trauma and burns 5,407 (15.6) 3,429 (15.4) 10,319 (15.6) 
Bleeding 1,177 (3.4) 675 (3.0) 2,106 (3.2) 
Unknown 8,092 (23.3) 5,541 (25.0) 15,472 (23.4) 
Donor ABO blood group, n (%)    
A 13,958 (40.2) 8,019 (36.1) 22,377 (33.9) 
B 1,551 (4.5) 510 (2.3) 2,084 (3.2) 
AB 9 (0.03) 1 (0.0) 15 (0.0) 
O 16,736 (48.2) 12,216 (54.9) 30,469 (46.1) 
Rhesus antigen positivity, n (%) 26,949 (77.6) 14,094 (63.4) 42,065 (63.6) 
Missing blood group, n (%) 2,468 (7.1) 1,494 (6.7) 11,156 (16.9) 
 
* Percentages do not add up until 100%. In ‘total’ are also apheresis products (2.7%) and products with 
unknown storage time (11.1%) included.  
† Expressed per number of platelet concentrates  
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Table 3. Incidence rate ratio for positive blood culture per number of old platelet concentrates, 
stratified on total number of platelet transfusions during a window period of one, three, five, or seven 
days. 
Incidence rate ratios with 95% confidence intervals are adjusted for hospital, rhesus D blood group, and 
day of the week. Transfusion of only fresh platelet concentrates were used as reference. Incidences are 
depicted in table 2 of the online appendix. 
Total 
number of 
platelet 
transfusions 
Number of 
old platelet 
concentrates 
Window period 
1 day 3 days 5 days 7 days 
1 0 ref ref ref ref 
1 1 0.57 (0.37-0.87) 0.87 (0.62-1.22) 0.79 (0.57-1.08) 0.87 (0.64-1.18) 
2 0 ref ref ref ref 
2 1 1.54 (0.64-3.71) 0.87 (0.53-1.44) 0.92 (0.58-1.43) 1.08 (0.72-1.63) 
2 2 1.11 (0.53-2.31) 0.98 (0.62-1.54) 0.88 (0.55-1.42) 0.95 (0.62-1.47) 
3* 0 ref ref ref ref 
3* 1 2.39 (0.40-14.31) 1.05 (0.39-2.81) 1.30 (0.65-2.61) 1.09 (0.59-2.02) 
3* 2 5.10 (1.13-23.00) 1.87 (0.75-4.63) 1.88 (0.97-3.65) 1.24 (0.65-2.36) 
3* 3 1.94 (0.43-8.71) 0.21 (0.03-1.63) 0.79 (0.29-2.18) 0.87 (0.36-2.09) 
≥4 0 N/A† ref ref ref 
≥4 1 N/A† 1.10 (0.35-3.41) 1.18 (0.62-2.23) 1.07 (0.59-1.91) 
≥4 2 N/A† 1.40 (0.52-3.78) 0.84 (0.42-1.68) 1.08 (0.61-1.91) 
≥4 3 N/A† 0.76 (0.17-3.42) 1.03 (0.49-2.14) 1.26 (0.68-2.33) 
≥4 ≥4 N/A† 1.64(0.70-3.80) 1.20 (0.66-2.17) 1.37 (0.81-2.33) 
 
* For the 1 day window period. the total number of platelet transfusions is 3 or more, as hardly any 
patient received 4 or more transfusions within 1 day. 
† Not applicable, insufficient number of patients received ≥4 transfusions in the 1 day window period. 
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Figure 1. Examples of cumulative exposure during a seven-day window period 
 
A) All transfusions during the window period are counted. Day 8 is the day of follow-up.  
B) The next window period starts one day later.  
C) If a transfusion is given at the follow-up day, this window period is excluded.  
D) Positive blood culture at day of follow-up 
E) After a positive blood culture patients are censored for 14 days.  
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Figure 2. Crude estimates of incidence rates of a positive blood culture after transfusion of 1, 2, 3 and 
≥4 platelet concentrates during different window periods. 
The number of analyzed patients and the total follow-up time differed among the window periods, since 
patients were only considered at risk if they received at least one platelet concentrate during the 
window period and no transfusion at the day of follow-up. This means that in the window period of one 
day, a transfusion contributed only to one window period and one day of follow-up was counted. In a 
sliding window period of seven days with steps of one day, a day of transfusion contributed to seven 
subsequent window periods, and seven days of follow-up could be counted.  
 
 
 
*IR (CI), incidence rate, expressed per 1000 patient-days of follow-up. 
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Figure 3. Incidence rate ratio of a positive blood culture after receiving at least one old platelet 
concentrate compared to transfusion of only fresh platelet concentrates.  
IRRs with 95% confidence interval are presented overall and stratified by number of total platelet 
transfusions during a window period of one, three, five, and seven days. If a patient received several 
platelet concentrates during the window period, no differentiation was made whether only one or more 
products were old. Incidence rate ratios are adjusted for hospital, rhesus D blood group, and day of the 
week. Overall estimate is also adjusted for number of platelet transfusions (1, 2, 3, ≥4).  
Panel A) Entire cohort  
Panel B) Patients with hematological malignancy or aplastic anemia 
The corresponding numbers are given in the online appendix.  
 
